Ji Yun, Song Hongyun, Li Libin
Department of Surgical Intensive Care Unit, The Second Affiliated Hospital, School of Medicine, Zhejiang University, 88 Jiefang Road, Hangzhou, Zhejiang, China.
Department of Rehabilitation in Traditional Chinese Medicine, The Second Affiliated Hospital, School of Medicine, Zhejiang University, 88 Jiefang Road, Hangzhou, Zhejiang, China.
Crit Care. 2025 May 15;29(1):193. doi: 10.1186/s13054-025-05441-4.
The global health burden of sepsis is immense, characterized by significant loss of life and high healthcare costs. Traditional Chinese medicine (TCM), with its over two millennia of clinical practice in China, has gained attention as a potential adjunctive approach for sepsis. Here, we evaluated TCM applications in sepsis management, highlighting both potential benefits and methodological limitations of existing clinical evidence. Although various TCM preparations have been evaluated for sepsis treatment, the vast majority lack robust clinical evidence. Xuebijing Injection represents a rare example that has demonstrated efficacy in a large-scale, multicenter, randomized, double-blind, placebo-controlled trial. In contrast, the evidence supporting other preparations such as Shenfu and Shenmai Injections comes primarily from smaller, single-center studies with significant methodological limitations. There is a clear need for more high-quality, multicenter randomized controlled trials to rigorously evaluate these potentially beneficial but currently insufficiently validated TCM preparations. The pharmacological effects and underlying mechanisms of some bioactive compounds derived from TCM medications have been elucidated, shedding light on the potential of TCM-based anti-sepsis drug discovery. We underscore the importance of continued research to better integrate TCM with modern sepsis management, paving the way for the development of evidence-based TCM treatments for this challenging condition.
脓毒症的全球健康负担极为巨大,其特征是大量生命损失和高昂的医疗成本。中医在中国有着两千多年的临床实践,作为脓毒症的一种潜在辅助治疗方法已受到关注。在此,我们评估了中医在脓毒症管理中的应用,强调了现有临床证据的潜在益处和方法学局限性。尽管多种中药制剂已针对脓毒症治疗进行了评估,但绝大多数缺乏有力的临床证据。血必净注射液是一个罕见的例子,它在一项大规模、多中心、随机、双盲、安慰剂对照试验中已证明具有疗效。相比之下,支持诸如参附注射液和参麦注射液等其他制剂的证据主要来自规模较小、存在重大方法学局限性的单中心研究。显然需要更多高质量的多中心随机对照试验来严格评估这些潜在有益但目前验证不足的中药制剂。一些源自中药的生物活性化合物的药理作用及潜在机制已得到阐明,为基于中医的抗脓毒症药物研发潜力提供了线索。我们强调持续研究以更好地将中医与现代脓毒症管理相结合的重要性,为针对这一具有挑战性病症的循证中医治疗方法的发展铺平道路。
J Am Coll Cardiol. 2017-6-20
Zhongguo Zhong Yao Za Zhi. 2023-4
Zhongguo Zhong Yao Za Zhi. 2015-9
J Ethnopharmacol. 2025-2-11
N Engl J Med. 2024-12-5
Phytomedicine. 2025-1
Nat Plants. 2024-12
Pharmacol Ther. 2024-12